Why is ResMed stock sliding today?
ResMed shares fell about 5.5% pre-open after the company reported mixed Q4 FY2026 results. Non-GAAP EPS was $2.95, above the ~$2.89 consensus, but revenue was $1.46B, slightly below ~$1.47B. ResMed’s first full-year FY2027 guidance implied 5–7% core revenue growth, plus a $75M Astral ventilator safety headwind, with MatrixCare divestiture and Noctrix acquisition expected to dilute EPS. Analysts cut price targets.
How this was made
The 30-second read
Why it matters
The stock decline is attributed to a revenue miss, a step-down in guided core revenue growth, a $75M Astral ventilator field-safety headwind, and EPS dilution from a pending MatrixCare divestiture plus a recently closed Noctrix Health acquisition.
Market read
Investors are repricing FY2027 growth and near-term EPS due to guidance conservatism and safety-action revenue headwinds, driving a sharp pre-open move.
What to watch
The article does not quantify how much the MatrixCare divestiture and Noctrix acquisition affect longer-term cash flow or margins, which could matter more than near-term EPS dilution.
Background
ResMed reported mixed Q4 FY2026 results and issued its inaugural full-year FY2027 guidance, which investors expected to be cleaner.
Ticker impact
ResMed shares slide 5.5% pre-open after mixed Q4 results and first-ever full-year FY2027 guidance with only 5–7% core revenue growth.
Bearish bias for the next several sessions as investors reprice FY2027 growth and margin risk from the Astral headwind and EPS dilution.
The article cites concrete, company-specific disclosures: revenue miss, cautious inaugural full-year guidance, a $75M Astral headwind, and EPS dilution from MatrixCare divestiture and Noctrix acquisition, all tied to the same-day pre-open selloff.
Market effects
Could pressure sentiment across sleep and respiratory device peers if investors generalize the growth deceleration and safety-action revenue headwind risk.
Primarily US single-name risk, with limited macro support as major indices were flat/modestly higher.
Limited direct global spillover beyond medical device investor sentiment around guidance conservatism and post-safety-action revenue impacts.
Counterpoint
The EPS beat (non-GAAP $2.95 vs ~$2.89) suggests profitability may be holding up, so the selloff may overreact to revenue growth deceleration and one-time headwinds.
Key entities
- companyResMed
Sleep and respiratory care device maker whose Q4 results and inaugural FY2027 guidance triggered a pre-open selloff.
- product_lineAstral ventilator
Ventilator line tied to a field safety action that creates a $75M revenue headwind in FY2027 guidance.
- business_unitMatrixCare
Software business pending divestiture expected to dilute EPS in the year ahead.
- acquisition_targetNoctrix Health
Health acquisition completed for $340M, expected to dilute EPS in the year ahead.
